MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc., (“OBI”) (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that a recently published study in the Journal of Cardiothoracic and Vascular Anesthesia provides evidence that levosimendan provides significant renal benefits to patients undergoing mitral valve surgery. The study was a double blinded, randomized, controlled trial of 128 patients with low ejection fraction (EF<45%) undergoing mitral valve surgery. As the authors reference, patients with low ejection fraction undergoing mitral valve surgery are at risk for adverse outcomes, including a significant risk for acute kidney injury. A link to access “In Press” version of this publication is found here http://www.jcvaonline.com/article/S1053-0770(13)00508-9/fulltext
Help employers find you! Check out all the jobs and post your resume.
